Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
In brief, in English
This funding opportunity supports efficient and innovative natural history studies to advance medical product development in rare diseases with unmet medical needs. The provided excerpt does not specify eligible applicant types.
Written by a model from the publisher's text. The official page is the authority. How data is produced
The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.
Historique des changements
First seen 28 Sept 2026, last checked 22 Nov 2026. 1 recorded version.
- 28 Sept 2026 · 50c37cb53a11